Reuters logo
BRIEF-Zosano Pharma says its transdermal therapeutic M207 meets both co-primary endpoints
February 13, 2017 / 2:08 PM / 8 months ago

BRIEF-Zosano Pharma says its transdermal therapeutic M207 meets both co-primary endpoints

Feb 13 (Reuters) - Zosano Pharma Corp

* Zosano pharma announces 3.8mg dose of m207, its novel transdermal therapeutic, meets both co-primary endpoints in the Zotrip pivotal efficacy trial in migraine

* 41.5% of patients experienced freedom from pain at 2 hours versus. 14.3% for placebo

* 3.8mg dose achieved significance in secondary endpoints of pain freedom at 45 minutes

* Zosano Pharma Corp - lead product candidate, M207, achieved both co-primary endpoints in recently completed Zotrip trial

* Zosano Pharma Corp - M207 was well-tolerated with no serious adverse events Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below